Ai In Point Of Care Hematology Market Size, Share and Outlook - Growth Analysis Report and Forecast Trends 2026-2030

The AI in Point of Care Hematology market encompasses smart analyzers, digital morphology platforms, and AI-assisted interpretive software deployed at or near the patient site for complete blood count (CBC), white blood cell differential, and related hematology testing. Having reached approximately USD 1.18 billion in 2025 and valued at USD 1.401 billion in 2026, the segment is growing materially faster than the conventional hematology diagnostics market, which advances in the mid-single digits, with an 18.76% CAGR. The premium growth rate reflects the value added by AI layers on top of an already expanding point-of-care diagnostics base.

Demand is being lifted by the rising global burden of hematologic conditions, including anemia, leukemias, lymphomas, and infection-related blood abnormalities that require frequent monitoring. Healthcare systems are simultaneously under pressure to shorten time-to-result, reduce dependence on expert microscopists, and manage workforce shortages in laboratory medicine, gaps that AI-enabled POC hematology is well suited to close. Regulatory and reimbursement support for rapid, decentralized testing further reinforces uptake.

The market can be segmented by component (analyzers, reagents/consumables, software and AI services), by application (CBC testing, differential leukocyte counting, malaria and infection screening, anemia management), and by end user (hospitals, diagnostic centers, ambulatory care, and home care). North America currently leads on the back of advanced healthcare infrastructure, favorable reimbursement, and early AI adoption, while Asia-Pacific is expected to be the fastest-growing region due to expanding healthcare access and large patient populations in China, India, and Southeast Asia.

What are the recent trends and outlook?

Key trends shaping the next phase include the migration of AI capabilities from cloud to on-device inference for faster results, the rise of digital morphology replacing manual microscopy, and tighter integration of POC hematology data with electronic health records and telehealth platforms. Vendors are also pursuing multi-modal AI that combines blood count data with clinical and molecular information to improve diagnostic precision. Over the forecast period through 2031, the market is expected to broaden from single-parameter CBC interpretation toward comprehensive AI-driven hematology decision support at the bedside.